NCT00685568View on ClinicalTrials.gov

Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 21, 2002

Primary Completion Date

April 21, 2006

Study Completion Date

April 21, 2006

Conditions
Colorectal CancerPrecancerous Condition
Interventions
DRUG

celecoxib

Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.

OTHER

placebo

Orally, twice daily for 3 months

Trial Locations (4)

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

77030

Texas Children's Hospital, Houston

University of Texas Medical School at Houston, Houston

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00685568 - Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis | Biotech Hunter | Biotech Hunter